Association of ORM1 rs150611042 with biomarkers of thrombin generation in 4 independent studies
| ORM1 rs150611042 C/A . | MARTHA, N = 714 . | 3C, N = 1253 . | MARTHA12, N = 726 . | FITENAT, N = 528 . | Combined,* N = 3221 . |
|---|---|---|---|---|---|
| Minor allele frequencies | 0.089 | 0.082 | 0.096 | 0.095 | |
| Lag time | |||||
| β† (SE) | −0.329 (0.086) | −0.343 (0.096) | −0.439 (0.084) | −0.280 (0.099) | −0.354 (0.045) |
| P | 1.53 × 10−4 | 3.85 × 10−4 | 2.46 × 10−7 | 5.04 × 10−3 | 7.11 × 10−15 |
| ETP | |||||
| β (SE) | −0.041 (0.016) | −0.083 (0.018) | −0.024 (0.017) | −0.013 (0.017) | −0.038 (0.009) |
| P | .015 | 9.31 × 10−6 | .147 | .449 | 8.41 × 10−6 |
| Peak | |||||
| β (SE) | −8.379 (6.107) | −6.557 (5.516) | 8.730 (6.286) | −0.984 (4.592) | −2.013 (2.748) |
| P | .171 | .233 | .165 | .830 | .464 |
| ORM1 rs150611042 C/A . | MARTHA, N = 714 . | 3C, N = 1253 . | MARTHA12, N = 726 . | FITENAT, N = 528 . | Combined,* N = 3221 . |
|---|---|---|---|---|---|
| Minor allele frequencies | 0.089 | 0.082 | 0.096 | 0.095 | |
| Lag time | |||||
| β† (SE) | −0.329 (0.086) | −0.343 (0.096) | −0.439 (0.084) | −0.280 (0.099) | −0.354 (0.045) |
| P | 1.53 × 10−4 | 3.85 × 10−4 | 2.46 × 10−7 | 5.04 × 10−3 | 7.11 × 10−15 |
| ETP | |||||
| β (SE) | −0.041 (0.016) | −0.083 (0.018) | −0.024 (0.017) | −0.013 (0.017) | −0.038 (0.009) |
| P | .015 | 9.31 × 10−6 | .147 | .449 | 8.41 × 10−6 |
| Peak | |||||
| β (SE) | −8.379 (6.107) | −6.557 (5.516) | 8.730 (6.286) | −0.984 (4.592) | −2.013 (2.748) |
| P | .171 | .233 | .165 | .830 | .464 |
Abbreviations are explained in Table 1.
Combined results were derived from a meta-analysis of the 4 studies under the framework of an inverse-variance weighting fixed-effect model. No heterogeneity was observed across cohorts, I2 = 1.67 (P = .795), I2 = 8.59 (P = 0.072), and I2 = 4.74 (P = .314) for lag time, ETP, and peak, respectively.
Additive effects associated with the rs150611042-A allele, adjusted for age, sex, oral contraceptive therapy (except in 3C), and on first 4 principal components (in MARTHA and 3C). In 3C, as well in 25 MARTHA patients, imputed allele dosage was used. Otherwise, the exact allele count derived from wet-laboratory genotyping was used. Association was tested by use of a linear regression model.